Home » Topics » BioWorld Science

BioWorld Science
RSS

miR-7-5p and miR-375-3p: new circulating markers of pituitary NETs

Sep. 3, 2021

JDQ-443: a mutant-selective, irreversible inhibitor of KRAS G12C with an unprecedented binding mode

Sep. 3, 2021

New Drosophila model casts light on cancer cachexia

Sep. 2, 2021

Bristol Myers Squibb exercises option to Evotec's EVT-8683

Sep. 2, 2021

Alligator and Scandion conclude collaboration evaluating mitazalimab with SCO-101 and chemotherapy

Sep. 2, 2021

Brickell licenses rights to Voronoi's DYRK1A inhibitors

Sep. 2, 2021

Innovent licenses rights to GenFleet's KRAS G12C inhibitor GFH-925

Sep. 2, 2021

Discovery of novel potent and reversible MAGL inhibitors

Sep. 2, 2021

New compounds reduce intracellular c-di-GMP content in Pseudomonas aeruginosa

Sep. 2, 2021

Discovery of novel GluN2B PAMs as potential therapeutics for Alzheimer's disease

Sep. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...